{"classes":[{"categories":[{"measurements":[{"comment":"Below level of detection.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Below level of detection.","groupId":"OG001","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Pre-Dose on Day 1 of Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4880","value":"13300"},{"groupId":"OG001","spread":"5060","value":"11200"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Before End of Infusion on Day 1 of Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1880","value":"7200"},{"groupId":"OG001","spread":"1670","value":"6860"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"title":"Post Infusion on Day 1 of Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"58.3","value":"144"},{"groupId":"OG001","spread":"48.1","value":"126"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Pre-Dose on Day 1 of Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3590","value":"13900"},{"groupId":"OG001","spread":"5090","value":"11300"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Before End of Infusion on Day 1 of Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1630","value":"7180"},{"groupId":"OG001","spread":"2200","value":"6540"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Post Infusion on Day 1 of Cycle 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Plasma concentration of carboplatin in the Global population.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received intravenous infusions of placebo in combination with carboplatin to achieve an initial target AUC of 5 mg/mL/min followed by etoposide 100 mg/m\\^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m\\^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) placebo on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.","id":"OG000","title":"Placebo + Carboplatin + Etoposide"},{"description":"Participants received intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) followed by etoposide 100 milligrams per square meter (mg/m\\^2) on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m\\^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) atezolizumab 1200 mg on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.","id":"OG001","title":"Atezolizumab + Carboplatin + Etoposide"}],"paramType":"MEAN","populationDescription":"PK analyses were based on PK observations from all participants who had received atezolizumab, carboplatin, or etoposide treatment and who provided at least one evaluable atezolizumab PK sample.","reportingStatus":"POSTED","timeFrame":"Predose, before end of infusion, and after end of carboplatin infusion on Day 1 of Cycle 1 and Cycle 3 (cycle = 21 days)","title":"Plasma Concentration of Carboplatin in the Global Population","type":"SECONDARY","unitOfMeasure":"ng/mL"}